Vanguard Fiduciary Trust
ACAD icon

Vanguard Fiduciary Trust’s Acadia Pharmaceuticals ACAD Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.1M Buy
912,370
+36,650
+4% +$806K 0.01% 1333
2026
Q1 		$19.5M Buy
+875,720
New +$20.9M ﹤0.01% 1348

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 94.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Fiduciary Trust's ACAD Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Acadia Pharmaceuticals (ACAD) stake by 4.2% in Q2 2026, buying an estimated $806K and bringing the position to 912,370 shares worth $23.1M. The position accounts for 0.01% of the portfolio, ranked #1333.

Vanguard Fiduciary Trust first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. 350 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Vanguard Fiduciary Trust held 912,370 shares of Acadia Pharmaceuticals worth $23.1M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 36,650 Acadia Pharmaceuticals shares in Q2 2026, an estimated $806K.
  • Acadia Pharmaceuticals made up 0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1333 holding.
  • Vanguard Fiduciary Trust first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.